Changzhou Qianhong Biopharma Co., Ltd. (002550) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Changzhou Qianhong Biopharma Co., Ltd.

Why is Changzhou Qianhong Biopharma Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 0.53% and Operating profit at 28.28% over the last 5 years

The company has declared Positive results for the last 3 consecutive quarters

ROCE(HY) Highest at 16.21%
DEBT-EQUITY RATIO (HY) Lowest at -39.65 %
INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost

With ROE of 15.34%, it has a fair valuation with a 3.28 Price to Book Value

Over the past year, while the stock has generated a return of 39.09%, its profits have risen by 67.7% ; the PEG ratio of the company is 0.3
At the current price, the company has a high dividend yield of 1.8

Market Beating Performance

The stock has generated a return of 39.09% in the last 1 year, much higher than market (China Shanghai Composite) returns of 15.18%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Changzhou Qianhong Biopharma Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Changzhou Qianhong Biopharma Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Changzhou Qianhong Biopharma Co., Ltd.

-100.0%

1.48

44.03%

China Shanghai Composite

15.19%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.53%

EBIT Growth (5y)

28.28%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.40

Sales to Capital Employed (avg)

0.69

Tax Ratio

16.44%

Dividend Payout Ratio

42.86%

Pledged Shares

Institutional Holding

ROCE (avg)

11.99%

ROE (avg)

8.97%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.28

EV to EBIT

17.43

EV to EBITDA

15.10

EV to Capital Employed

4.68

EV to Sales

5.04

PEG Ratio

0.32

Dividend Yield

1.78%

ROCE (Latest)

26.86%

ROE (Latest)

15.34%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company

ROCE(HY)

Highest at 16.21%

DEBT-EQUITY RATIO (HY)

Lowest at -39.65 %

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

RAW MATERIAL COST(Y)

Fallen by -6.17% (YoY

CASH AND EQV(HY)

Highest at CNY 1,795.93 MM

OPERATING PROFIT(Q)

Highest at CNY 175.7 MM

PRE-TAX PROFIT(Q)

Highest at CNY 185.49 MM

NET PROFIT(Q)

Highest at CNY 159.67 MM

EPS(Q)

Highest at CNY 0.13

-2What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Changzhou Qianhong Biopharma Co., Ltd.

Debt-Equity Ratio

Lowest at -39.65 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Operating Profit

Highest at CNY 175.7 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Pre-Tax Profit

Highest at CNY 185.49 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Pre-Tax Profit

At CNY 185.49 MM has Grown at 59.35%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 159.67 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Net Profit

At CNY 159.67 MM has Grown at 53.92%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.13

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Cash and Eqv

Highest at CNY 1,795.93 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -6.17% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales